{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-067662","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.130174+00:00","generated_at":"2026-06-01T06:53:02.903208+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cullinan reports Phase 2b zipalertinib data: 39% ORR in post-amivantamab NSCLC patients","bullets":["ORR of 39% (confirmed) and DCR of 94% in 18 evaluable patients; median DOR and PFS not yet reached.","No grade 4 or 5 treatment-related adverse events; safety profile manageable and consistent with prior data.","Data cut-off Jan 12, 2024; patients received median 3 prior therapies including chemo, anti-PD1/L1, and EGFR TKI.","Enrollment in pivotal REZILIENT1 trial (Modules B2 and C) on track to complete by end of 2024.","Partnership with Taiho: upfront $275M plus up to $130M in milestones; 50/50 US profit share."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-067662","json":"https://secwatch.observer/filing/0000950170-24-067662.json","markdown":"https://secwatch.observer/filing/0000950170-24-067662.md","text":"https://secwatch.observer/filing/0000950170-24-067662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024067662/0000950170-24-067662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024067662/cgem-20240601.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:53:02.903208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}